Gal Chen
Gal Chen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Avi Schroeder
The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies Department of Chemical Engineering Technion – Israel Institute of Technology Haifa 32000 Israel
5 shared publications - Jeny Shklover
The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering
3 shared publications Yuval Richtman
TechnionIsrael Institute of Technology
3 shared publicationsBruno Sarmento
Universidade do Porto
2 shared publicationsDevora Cohen-Karni
Lake Erie College of Osteopathic Medicine
2 shared publicationsJanna Shainsky-Roitman
The Luis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion, Haifa 32000, Israel
2 shared publications
Latest Publications
- 17 September 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (10) , 4381
Correction to “Phosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity”
- 17 September 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (10) , 4381
Correction to “Phosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity”
- Open Access
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (7) , 2823-2836
Phosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity
Energy-supplying molecules are essential for biological processes, particularly for transcription and translation. Cell-free protein synthesis (CFPS) systems are powerful tools for in vitro protein production, offering flexibility for applications ranging from high-throughput protein screening to therapeutic protein production. However, energy regeneration in CFPS remains a key challenge, particularly for large-scale or resource-constrained settings. In this study, we introduce phosphoserine (PS) as a simple, cost-effective alternative secondary energy source, capable of partially or fully replacing 3-phosphoglycerate (PGA), the commonly used energy donor in E. coli lysate-based CFPS, whose availability is often limited. By supplementing CFPS reactions with PS, we demonstrate significant improvements in protein yield and cost-efficiency, achieving a 2-fold increase in protein production. Importantly, PS enhancement is maintained across lysate batches and protein targets. Furthermore, we offer affordable CFPS compositions that retain protein synthesis, making the system more accessible for resource-limited settings. Additionally, we show that higher PS concentrations, while reducing final protein yield, extend the reaction duration by more than 2-fold. Therefore, the incorporation of PS as an alternative energy donor enables a tunable modality for balancing protein yield, reaction longevity, and cost. Our data support a model in which PS enhances CFPS via the serine biosynthesis pathway by modulating flux between serine production and glycolysis to support ATP regeneration. Lastly, we validate the use of these optimized CFPS compositions within synthetic cells (SCs). This study establishes PS as a promising energy source for E. coli lysate-based CFPS systems, paving the way for enhanced and economical protein synthesis platforms tailored to diverse clinical, biotechnological, and industrial needs.
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (7) , 2823-2836
Open AccessPhosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity
Energy-supplying molecules are essential for biological processes, particularly for transcription and translation. Cell-free protein synthesis (CFPS) systems are powerful tools for in vitro protein production, offering flexibility for applications ranging from high-throughput protein screening to therapeutic protein production. However, energy regeneration in CFPS remains a key challenge, particularly for large-scale or resource-constrained settings. In this study, we introduce phosphoserine (PS) as a simple, cost-effective alternative secondary energy source, capable of partially or fully replacing 3-phosphoglycerate (PGA), the commonly used energy donor in E. coli lysate-based CFPS, whose availability is often limited. By supplementing CFPS reactions with PS, we demonstrate significant improvements in protein yield and cost-efficiency, achieving a 2-fold increase in protein production. Importantly, PS enhancement is maintained across lysate batches and protein targets. Furthermore, we offer affordable CFPS compositions that retain protein synthesis, making the system more accessible for resource-limited settings. Additionally, we show that higher PS concentrations, while reducing final protein yield, extend the reaction duration by more than 2-fold. Therefore, the incorporation of PS as an alternative energy donor enables a tunable modality for balancing protein yield, reaction longevity, and cost. Our data support a model in which PS enhances CFPS via the serine biosynthesis pathway by modulating flux between serine production and glycolysis to support ATP regeneration. Lastly, we validate the use of these optimized CFPS compositions within synthetic cells (SCs). This study establishes PS as a promising energy source for E. coli lysate-based CFPS systems, paving the way for enhanced and economical protein synthesis platforms tailored to diverse clinical, biotechnological, and industrial needs.
- Top Cited PapersOpen Access
- 16 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36106-36128
AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small molecules, thereby enhancing brain delivery and gene expression. Screening brain-targeted mRNA-LNPs in central nervous system (CNS) in vitro models and through intravenous administration in mice demonstrated that acetylcholine-conjugated LNPs achieved superior brain tropism and gene expression, outperforming LNP modifications with nicotine, glucose, memantine, cocaine, tryptophan, and other small molecules. An artificial intelligence (AI)-based model designed to predict the BBB permeability of small-molecule ligands showed strong alignment with our experimental results, providing in vivo validation of its predictive capacity. Cell-specific biodistribution analysis in Cre-reporter Ai9 mice showed that acetylcholine-functionalized LNPs preferentially transfected neurons and astrocytes following either intravenous or intracerebral administration. Mechanistic studies suggest that acetylcholine-LNP uptake is mediated by the functional engagement of acetylcholine receptors (AchRs) followed by endocytosis, which synergistically enhances intracellular mRNA delivery. Moreover, acetylcholine-LNPs successfully crossed a human BBB-on-a-chip model, enabling transgene expression in human iPSC-derived neurons. Their effective penetration and transfection in human brain organoids further support their potential activity in human-based systems. These findings establish a predictive and modular framework for engineering CNS-targeted LNPs, advancing precision gene delivery for brain disorders.
- 16 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36106-36128
Top Cited PapersOpen AccessAI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small molecules, thereby enhancing brain delivery and gene expression. Screening brain-targeted mRNA-LNPs in central nervous system (CNS) in vitro models and through intravenous administration in mice demonstrated that acetylcholine-conjugated LNPs achieved superior brain tropism and gene expression, outperforming LNP modifications with nicotine, glucose, memantine, cocaine, tryptophan, and other small molecules. An artificial intelligence (AI)-based model designed to predict the BBB permeability of small-molecule ligands showed strong alignment with our experimental results, providing in vivo validation of its predictive capacity. Cell-specific biodistribution analysis in Cre-reporter Ai9 mice showed that acetylcholine-functionalized LNPs preferentially transfected neurons and astrocytes following either intravenous or intracerebral administration. Mechanistic studies suggest that acetylcholine-LNP uptake is mediated by the functional engagement of acetylcholine receptors (AchRs) followed by endocytosis, which synergistically enhances intracellular mRNA delivery. Moreover, acetylcholine-LNPs successfully crossed a human BBB-on-a-chip model, enabling transgene expression in human iPSC-derived neurons. Their effective penetration and transfection in human brain organoids further support their potential activity in human-based systems. These findings establish a predictive and modular framework for engineering CNS-targeted LNPs, advancing precision gene delivery for brain disorders.
- Open Access
- 12 September 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (38)
Implanted synthetic cells trigger tissue angiogenesis through de novo production of recombinant growth factors
Progress in bottom-up synthetic biology has stimulated the development of synthetic cells (SCs), autonomous protein-manufacturing particles, as dynamic biomimetics for replacing diseased natural cells and addressing medical needs. Here, we report that SCs genetically encoded to produce proangiogenic factors triggered the physiological process of neovascularization in mice. The SCs were constructed of giant lipid vesicles and were optimized to facilitate enhanced protein production. When introduced with the appropriate genetic code, the SCs synthesized a recombinant human basic fibroblast growth factor (bFGF), reaching expression levels of up to 9⋅106protein copies per SC. In culture, the SCs induced endothelial cell proliferation, migration, tube formation, and angiogenesis-related intracellular signaling, confirming their proangiogenic activity. Integrating the SCs with bioengineered constructs bearing endothelial cells promoted the remodeling of mature vascular networks, supported by a collagen-IV basement membrane–like matrix. In vivo, prolonged local administration of the SCs in mice triggered the infiltration of blood vessels into implanted Matrigel plugs without recorded systemic immunogenicity. These findings emphasize the potential of SCs as therapeutic platforms for activating physiological processes by autonomously producing biological drugs inside the body.
- 12 September 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (38)
Open AccessImplanted synthetic cells trigger tissue angiogenesis through de novo production of recombinant growth factors
Progress in bottom-up synthetic biology has stimulated the development of synthetic cells (SCs), autonomous protein-manufacturing particles, as dynamic biomimetics for replacing diseased natural cells and addressing medical needs. Here, we report that SCs genetically encoded to produce proangiogenic factors triggered the physiological process of neovascularization in mice. The SCs were constructed of giant lipid vesicles and were optimized to facilitate enhanced protein production. When introduced with the appropriate genetic code, the SCs synthesized a recombinant human basic fibroblast growth factor (bFGF), reaching expression levels of up to 9⋅106protein copies per SC. In culture, the SCs induced endothelial cell proliferation, migration, tube formation, and angiogenesis-related intracellular signaling, confirming their proangiogenic activity. Integrating the SCs with bioengineered constructs bearing endothelial cells promoted the remodeling of mature vascular networks, supported by a collagen-IV basement membrane–like matrix. In vivo, prolonged local administration of the SCs in mice triggered the infiltration of blood vessels into implanted Matrigel plugs without recorded systemic immunogenicity. These findings emphasize the potential of SCs as therapeutic platforms for activating physiological processes by autonomously producing biological drugs inside the body.
- Open Access
- 28 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Synthetic cells with self-activating optogenetic proteins communicate with natural cells
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the design and implementation of bioluminescent intercellular and intracellular signaling mechanisms in synthetic cells, dismissing the need for an external light source. First, we engineer light generating SCs with an optimized lipid membrane and internal composition, to maximize luciferase expression levels and enable high-intensity emission. Next, we show these cells’ capacity to trigger bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent intracellular signaling with self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of controlling engineered processes inside tissues.
- 28 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessSynthetic cells with self-activating optogenetic proteins communicate with natural cells
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the design and implementation of bioluminescent intercellular and intracellular signaling mechanisms in synthetic cells, dismissing the need for an external light source. First, we engineer light generating SCs with an optimized lipid membrane and internal composition, to maximize luciferase expression levels and enable high-intensity emission. Next, we show these cells’ capacity to trigger bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent intracellular signaling with self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of controlling engineered processes inside tissues.